NEW YORK (GenomeWeb News) – Thermo Fisher Scientific and Intrinsic Bioprobes today announced an agreement to co-develop and market a mass spectrometry-based solution for researchers to do quantitative, high-throughput, and high resolution protein biomarker assays.
Under the agreement, IBI's proprietary immunoenrichment technology will be integrated with Thermo Fisher's sample handling and mass specs, providing "researchers with a more complete, higher-resolution view of the proteome," Thermo Fisher said in a statement.
Via a reseller agreement, the solution will initially be used to detect human parathyroid hormone, or PTH, and its variants, which have the potential to be used as biomarkers for bone disease and endocrinological disease.
Researchers at Thermo Fisher's Biomarkers Initiatives in Mass Spectrometry, or BRIMS, Center will collaborate with IBI to develop a mass spec immunoassay workflow for research laboratories. Thermo Fisher will market, distribute, and support the solution and the workflow.
Financial terms of the deal were not revealed.
In a statement, Mary Lopez, director of BRIMS, said the two companies have been collaborating for the past year to develop a quantitative assay for PTH and its variants. The work they've done "demonstrates a workflow that enables detection and quantification of very low abundance intact PTH, and more importantly, several novel PTH protein variants that cannot be detected using conventional assays," she said.
While mass specs can identify and quantify protein variants, researchers have been "stymied by the lack of an integrated, high-throughput mass spectrometry workflow that is robust and reproducible from laboratory to laboratory," the company added.
IBI's immunoenrichment technology is based on a patented pipette tip that integrates a high-throughput, high-binding capacity microcolumn activated with antibodies. The technology allows for the isolation and analysis of very low abundance proteins such as PTH in complex solutions. Compared to other immunoenrichment approaches, IBI's can capture more low abundance proteins, Thermo Fisher said.
Based in Tempe, Ariz., IBI develops technologies for proteomics and biomarker analysis.